Business
Further Agreement with Eli Li
Further Agreement with Eli Li.
About this update from Physiomics Plc
[{"type":"text","content":"\n RNS Number : 7733Y Physiomics PLC 14 July 2008 \n \nPhysiomics plc\nThe Magdalen Centre\nThe Oxford Science ParkRobert Robinson AvenueOxford\nOX4 4GAUK\n\nTel 01865 784980\nFax 08701 671931\n14 July 2008 \nPhysiomics plc ('Physiomics' or 'the Company')\nPhysiomics Technology in continued and expanded support of Lilly's Oncology Programs \nPhysiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a further agreement with Eli Lilly and Company ('Lilly') (NYSE: LLY), the global pharmaceutical company, to perform two new projects for in silico simulations in the field of oncology. Financial details of this agreement have not been disclosed. This follows the successful completion earlier this year of a specific project studying cancer cellular processes for drugs targeting the cell cycle (the natural process of controlling cell proliferation).\nThe overall aim of the first new project is to provide a rationale for the identification of patient subpopulations that could benefit from an undisclosed target inhibitor (drug candidate). Physiomics' role is to provide this rationale, based on identifying and illustrating the mechanisms underlying the response of cells with different genetic backgrounds to this class of inhibitors given alone and in combination with other drugs. \nFor the second project, a customised model will be produced which integrates various biomarkers currently being investigated by Lilly as functional readouts for proprietary undisclosed target (distinct from the above-mentioned target) inhibitors. The model will provide a rational mechanistic understanding of the involvement of these biomarkers in the functional response to the inhibitors. In so doing, the model will be used to select optimal dosing regimes for the drugs either alone or in combination with other drugs.\nDr Christophe Chassagnole, COO of Physiomics, said:\n'Clearly we are very pleased to be able to continue and expand our collaboration with Lilly following the satisfactory completion of a preliminary study design...